Ryan Sullivan, MD, director, Center for Melanoma, Massachusetts General Hospital, discusses findings from the phase 2 IGNYTE trial (NCT03767348) evaluating RP1 in combination with nivolumab (Opdivo) in patients with advanced melanoma who progressed on prior anti–PD-1 therapy.
Melanoma News
Post–PD-1 Data in Melanoma Offers Insight into IO Approaches
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.
Nivolumab Plus Relatlimab Fails to Improve RFS in Resected Stage III/IV Melanoma
Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.
Scientists discover the ‘roadmap’ that aggressive cancer uses to spread around the body – identifying ways to block its escape
Image of human melanoma tissue, with melanoma cells in green and purple extracellular matrix fibres arranged perpendicular at the border of the tumour. Credit Oscar Maiques Carlos